New Survey by Applied Data Research Analyzes Therapeutic and Commercial Factors in Treating Autoimmune Diseases

The TRAF1/C5 locus on chromosome 9 has been revealed to play a role in multiple autoimmune diseases including type 1 diabetes and systemic lupus erythematosus (SLE), according to new data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

Ovarian function can be preserved and disease activity controlled in women with severe systemic lupus erythematosus (SLE) when treated with a 6-month course of cyclophosphamide (CYC), a chemotherapy drug, followed by the immunosuppressant mycophenolate mofetil (MMF), according to a new study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

Systemic lupus erythematosus (SLE), commonly known as lupus, can affect nearly any part of the body, including the joints, skin, kidneys, heart, nervous system, and brain. Along with joint pain, muscle pain, unexplained fever, extreme fatigue, and skin rashes, neurologic and psychiatric events often accompany this autoimmune disease.

Swedish researchers, in collaboration with foreign colleagues, have identified a number of new genes that can be tied to the disease systemic lupus erythematosus, including a gene that hopefully might be used to treat the disease in the future by regulating the production of antibodies.

An international consortium of scientists has identified multiple genes that are linked to systemic lupus erythematosus, a devastating autoimmune disease that affects between 1 million and 2 million Americans.

A landmark genetic study has identified multiple genes linked to systemic lupus erythematosus (SLE), or lupus, a debilitating autoimmune disease that affects an estimated 1.4 million Americans.

Mayo Clinic researchers have shown that an immunosuppressive drug used in organ transplant cases is effective in reducing flare-ups in patients with systemic lupus erythematosus (SLE). SLE results in inflammation of connective tissues and can involve the skin, joints and kidneys.

The prognosis for systemic lupus erythematosus (SLE), an autoimmune disease that mainly affects women in their reproductive years, has improved recently, prompting a shift toward improving quality of life. For men with SLE, concerns have been raised about their future fertility.

36% of patients with refractory systemic lupus erythematosus (SLE or lupus) remain well after undergoing B-cell depletion therapy (BCDT) without needing further standard immunosuppressive agents, according to a study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

Treatment with belimumab resulted in a sustained improvement of systemic lupus erythematosus (SLE or lupus) disease activity in 46% of patients at week 52, according to a novel combined responder index in results presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

Medicaid is one of the nation's largest insurance programs, covering approximately 55 million people. Yet some studies suggest there is declining physician participation in the program, which limits access to enrolled patients, particularly to specialists. Systemic lupus erythematosus (SLE) is a chronic autoimmune condition whose sufferers face lifelong periods of disease flares and inflammation of numerous organ systems.